SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to activate immune checkpoints for the treatment of colon cancer. The program entails identifying small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially critical immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient's own immune system. Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders.
Small molecule drugs have been the mainstay of the pharmaceutical industry for nearly a century. Defined as any organic compound with low molecular weight, small molecule drugs have some distinct advantages as therapeutics, and performing development is of immense value to the big pharmaceutical companies.
Oncology Pharma is delighted to add this IP to its portfolio of assets that addresses therapeutics in what can lead to expanding both time and the quality of life for cancer patients.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the "Company") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
For additional Information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
email: [email protected]
SOURCE: Oncology Pharma Inc.
View source version on accesswire.com: